Early Drug Development

### Early Phase Trials

**[48Ga]-NeoB Positive**
- Requiring Radiation
  - HNSCC Cisplatin Ineligible Tumors
  - CD200R1 Immune Checkpoint Inhibitor
  - Intratumoral Injection

**NRG008**
- Phase I/IIa DNA-PK Inhibition & IMRT in Cisplatin-Ineligible Stage 3-4 Local-Regionally Advanced HNSCC
- PI: Khan, Sponsor: NRG

**VAR0233**
- Phase I/IIa Dose Escalation and Expansion of IV Administered 23ME-00610 in Advanced Solid Malignancies
- PI: Khan, Sponsor: 23andMe, Inc.

**VAR0226**
- Phase I/IIa GS-1811 (Afucosylated Anti-CCR8 Monoclonal Antibody) +/- Pembrolizumab in Advanced Solid Tumors
- PI: Chen, Sponsor: Gilead Sciences, Inc.

**VAR0235**
- Phase Ia/Ib, Open Label, Multicenter, Dose-Escalation Study to Evaluate Safety Pharmacokinetics & Activity of RO7502175 +/- Atezolizumab in Locally Advanced or Metastatic Solid Tumors
- PI: Chen, Sponsor: Genentech, Inc.

**VAR0218**
- Phase I/II HMBD-002-V4C76 (mAb) Mono-Therapy & in Combination w/ Pembrolizumab in Advanced Unresectable Recurrent or Metastatic Tumors
- PI: Tell, Sponsor: Hummingbird Bioscience, Inc.

**VAR0222**
- First-In-Human Phase I/IIa RBS2418 as +/- Pembrolizumab in Advanced Cancers
- PI: Chen, Sponsor: Palleon Pharmaceuticals

**VAR0226**
- Phase I/II E-602 As a Single Agent and in Combination w/ Pembrolizumab in Advanced Cancers
- PI: Khan, Sponsor: Genentech, Inc.

**VAR0225**
- Phase I/II CT Georgian 1038 As a Single Agent in Combination w/ pembrolizumab in Advanced Cancers
- PI: Khan, Sponsor: Genentech, Inc.

**VAR0206**
- Phase I/II Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XnAb24306 as Single Agent & in Combo w/ Atezolizumab in Locally Advanced or Metastatic Solid Tumors
- PI: Khan, Sponsor: Genentech, Inc.

**VAR0206**
- Phase I/II Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XnAb24306 as Single Agent & in Combo w/ Atezolizumab in Locally Advanced or Metastatic Solid Tumors
- PI: Khan, Sponsor: Genentech, Inc.

**VAR0206**
- Phase I/II Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XnAb24306 as Single Agent & in Combo w/ Atezolizumab in Locally Advanced or Metastatic Solid Tumors
- PI: Khan, Sponsor: Genentech, Inc.

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu